A combination of BET and PARP inhibition has demonstrated efficacy in inhibiting tumorigenesis in preclinical models of multiple cancer types, including pancreatic, breast, ovarian, prostate, and lung cancers [13, 15, 17, 22]. Here, PARP1 is linked to lung cancer.